A New Jersey mail-order pharmacy’s parry of a Food and Drug Administration enforcement action may test the agency’s power to regulate compounders — makers of medicinal mixtures for special needs of human and animal consumers.

In a cease-and-desist letter, the FDA accuses Wedgewood Village Pharmacy Inc. of violating federal law by manufacturing and selling “new drugs” not generally recognized by experts as safe or effective for their labeled use.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]